17:32 EST Agile Therapeutics files to sell $15M of common stock, Series E-1 warrants
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AGRX:
- Agile Therapeutics reports Q3 EPS ($1.47) vs ($3.10) last year
- Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Is AGRX a Buy, Before Earnings?
- Agile Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on Thursday, November 9, 2023